Zetonna is a brand name of ciclesonide nasal, approved by the FDA in the following formulation(s):
ZETONNA (ciclesonide - aerosol, metered; nasal)
Manufacturer: NYCOMED GMBH
Approval date: January 20, 2012
Strength(s): 0.037MG/INH [RLD]
Has a generic version of Zetonna been approved?
No. There is currently no therapeutically equivalent version of Zetonna available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zetonna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
Patent 5,482,934
Issued: January 9, 1996
Inventor(s): Calatayud; Jose & Conde; Jose R. & Luna; Manuel
Assignee(s): Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.)
The present invention relates to compounds of the formula: ##STR1## in which X.sub.1 and X.sub.2 correspond to H or F without distinction; R.sub.1 represents the following radicals: ##STR2## and R.sub.2 represents the radicals ##STR3## in the form of an R epimer, an S epimer, or a stereoisomeric mixture of the R and S epimers in terms of the orientation of the substituents on the carbon atom at position 22, novel intermediates and a method of their preparation by hydrolysis-ketalization, and use of such compounds as drugs and/or therapeutic agents.Patent expiration dates:
- October 24, 2017✓✓✓
- October 24, 2017
Medicinal aerosol formulations
Patent 5,605,674
Issued: February 25, 1997
Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
Assignee(s): Riker Laboratories, Inc.
A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.Patent expiration dates:
- February 25, 2014✓
- February 25, 2014
Medicinal aerosol formulations
Patent 5,683,677
Issued: November 4, 1997
Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
Assignee(s): Riker Laboratories, Inc.
A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.Patent expiration dates:
- November 4, 2014✓
- November 4, 2014
Seal configuration for aerosol canister
Patent 5,775,321
Issued: July 7, 1998
Inventor(s): Alband; Todd D.
Assignee(s): Minnesota Mining and Manufacturing Company
A dual seal configuration for an aerosol canister containing a medicinal aerosol formulation. The canister includes a vial body and valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation. The dual seal configuration reduces leakage of contents, and is particularly helpful where the formulation includes hydrofluorocarbon propellant and an ethanol cosolvent. The first seal can be selected to be a barrier to the formulation components, while the second seal can be relatively more labile to such components.Patent expiration dates:
- July 7, 2015✓
- July 7, 2015
Device for delivering an aerosol
Patent 6,006,745
Issued: December 28, 1999
Inventor(s): Marecki; Paul E.
Assignee(s): Minnesota Mining and Manufacturing Company
A device for delivering an aerosol comprises a casing member, a valve stem, and a sealing member, wherein the sealing member comprises a thermoplastic elastomer comprising of a copolymer of about 80-95 mole % ethylene and about 5-20 mole % of at least one comonomer wherein the comonomer(s) are 1-butene, 1-hexene, or 1-octene. The device is used with pharmaceutical formulations containing 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane as the propellant.Patent expiration dates:
- December 28, 2016✓
- December 28, 2016
Seal configuration for aerosol canister
Patent 6,036,942
Issued: March 14, 2000
Inventor(s): Alband; Todd D.
Assignee(s): 3M Innovative Properties Company
An aerosol canister for containing a medicinal aerosol formulation. The canister involves a vial body and a valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation.Patent expiration dates:
- April 30, 2013✓
- April 30, 2013
Medicinal aerosol products containing formulations of ciclesonide and related steroids
Patent 6,120,752
Issued: September 19, 2000
Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
Assignee(s): 3M Innovative Properties Company
Byk Gulden Lomberg Chemische Fabrik GmbH
A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.Patent expiration dates:
- May 13, 2018✓
- May 13, 2018
Medicinal aerosol formulation of ciclesonide and related compounds
Patent 6,264,923
Issued: July 24, 2001
Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
Assignee(s): 3M Innovative Properties Company
A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.Patent expiration dates:
- May 13, 2018✓
- May 13, 2018
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 20, 2015 - NEW PRODUCT
See also...
- Zetonna Consumer Information (Drugs.com)
- Ciclesonide Spray Consumer Information (Wolters Kluwer)
- Ciclesonide nasal Consumer Information (Cerner Multum)
- Ciclesonide Nasal Advanced Consumer Information (Micromedex)
- Ciclesonide AHFS DI Monographs (ASHP)
